10-Q: Bio Green Med Solution Faces Going Concern Doubt Amid Business Shift

Bio Green Med Solution's Q3 2026 report highlights revenue growth in its fire safety segment but reiterates substantial doubt about its ability to continue as a going concern.

Summary

• Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) has transitioned its primary business focus from biopharmaceuticals to fire safety protection and distribution, following the acquisition of Fitters Sdn. Bhd. in September 2025.
• For the nine months ended September 30, 2026, the company reported revenues of $1.6 million, a significant increase from $0.1 million in the same period of 2025, primarily from fire safety equipment sales.
• Despite revenue growth, the company continues to face substantial doubt regarding its ability to continue as a going concern, with cash and cash equivalents of $3.5 million expected to sustain operations only into the second quarter of 2027.
• A significant event is the pending business combination with Future NRG Sdn. Bhd. (FNRG), expected to close by December 31, 2026, where FNRG shareholders will own over 99% of the combined entity.
• The company received a Nasdaq notice on October 29, 2026, indicating its common stock does not meet the minimum bid price requirement of $1.00, with a 180-day grace period to regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued substantial doubt about the company's ability to continue as a going concern, despite a shift in business focus and some revenue growth.

Positives

• Revenue from the fire safety segment increased significantly to $1.6 million for the nine months ended September 30, 2026, from $0.1 million in the prior year period.
• Operating expenses, specifically general and administrative expenses, decreased substantially by $4.9 million for the nine months ended September 30, 2026, compared to the prior year, largely due to the reduction of one-time costs associated with previous changes in control.
• The company is actively pursuing a business combination with Future NRG Sdn. Bhd., which could provide a strategic path forward.
• The company received $794,403 in gross proceeds from a Securities Purchase Agreement with certain foreign accredited investors on June 10, 2026.

Negatives

• There is substantial doubt about the company's ability to continue as a going concern, with current liquidity expected to last only into the second quarter of 2027.
• The company's common stock is at risk of delisting from the Nasdaq Stock Market due to failing to meet the minimum bid price requirement of $1.00.
• The pending business combination with Future NRG Sdn. Bhd. will result in the Selling Shareholders owning over 99% of the combined company, significantly diluting existing shareholders.
• The company incurred a net loss of $1.05 million for the nine months ended September 30, 2026, compared to a net loss of $2.39 million in the same period of 2025.
• The company's goodwill impairment test as of September 30, 2026, showed a narrow cushion of less than $0.1 million, indicating a risk of future impairment charges.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, with potential for curtailment of operations, delays in development, cessation of operations, or bankruptcy if funding is not secured.
• The company's common stock may be delisted from the Nasdaq Stock Market if it fails to regain compliance with the minimum bid price requirement by April 27, 2027.
• The business combination with Future NRG Sdn. Bhd. is subject to termination if not closed by December 31, 2026.
• The company's goodwill is sensitive to fluctuations in its common stock price and control premium assumptions, with a potential for material non-cash impairment charges.
• Litigation from David Lazar against current and former directors poses a risk, although the company believes these actions are without merit.

Future Outlook

The company expects modest revenue growth in fire safety in the near term, with more elevated growth anticipated for fire safety equipment to service the expansion of data centers in Southern Malaysia. General and administrative expenditures are expected to be significantly lower in 2026 compared to 2025 due to the reduction of non-recurring costs. However, the company's ability to continue as a going concern is uncertain and depends on securing additional financing or a successful strategic transaction.

Management Comments

• The company is focused on advancing opportunities across distinct sectors (fire safety and biopharmaceuticals) whilst maintaining its commitment to driving long-term value creation for its stockholders.
• The company believes it would be an attractive candidate for a business combination due to the perceived benefits of being a publicly listed company, providing a transaction partner access to the public marketplace to raise capital.
• The Board of Directors believes it must consider all viable strategic alternatives that are in the best interests of its shareholders, including a merger, acquisition, share exchange, asset purchase, or similar transaction.

Industry Context

StockSavvy.ai notes that Bio Green Med Solution's strategic shift to the fire safety sector aligns with increasing demand for safety equipment driven by industrial and commercial expansion, particularly in regions like Southern Malaysia with data center growth. However, the company's ongoing financial precariousness and potential Nasdaq delisting overshadows this sector-specific opportunity.

Comparison to Industry Standards

• The company's revenue growth in the fire safety segment, while significant year-over-year, is from a low base ($1.6 million for nine months ended Sep 30, 2026). Industry benchmarks for established fire safety companies would typically involve revenues in the tens or hundreds of millions.
• The company's gross margins of approximately 22% for the nine months ended September 30, 2026, are within a reasonable range for distribution businesses, but specific industry comparisons would require detailed product-level margin analysis.
• The substantial decrease in general and administrative expenses (76% for nine months ended Sep 30, 2026) reflects a significant cost-cutting effort, which is a positive sign for operational efficiency, but also highlights the previous high overheads potentially related to its prior biopharmaceutical focus.

Management Changes

Legal Proceedings

• David Lazar filed an action in the Supreme Court of the State of New York against current and former directors, alleging breach of fiduciary duty and seeking $12 million in damages. Defendants have moved to dismiss.
• David Lazar filed a separate action against Datuk Dr. Doris Wong Sing Ee, alleging breach of contract, breach of implied covenant of good faith and fair dealing, conversion, and unjust enrichment, seeking $629,501.36. The court dismissed all causes of action except breach of contract, and the defendant is appealing.
• The company believes these legal actions are without merit and does not expect them to have a material adverse effect on its financial condition, results of operations, or cash flows.

Stakeholder Impact

• Shareholders face significant dilution from the pending business combination with Future NRG Sdn. Bhd., where they will own less than 1% of the combined entity.
• Shareholders also face the risk of losing their entire investment if the company cannot secure funding and is forced to file for bankruptcy.
• Preferred stockholders will continue to receive dividends on the 6% Convertible Exchangeable Preferred Stock, subject to board declaration and availability of funds.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by April 27, 2027, potentially through a reverse stock split or other alternatives.
• Close the Business Combination Agreement with Future NRG Sdn. Bhd. by December 31, 2026, subject to shareholder approval and other conditions.
• Conduct an interim goodwill impairment test in the fourth quarter of 2026.
• Continue to evaluate the payment of quarterly cash dividends on the 6% Convertible Exchangeable Preferred Stock.

Key Dates

Recommendation

The company's continued substantial doubt regarding its going concern status, coupled with the significant dilution from the pending business combination and the risk of Nasdaq delisting, presents a highly unfavorable risk-reward profile for investors. While the shift to the fire safety sector shows some revenue growth, it is insufficient to offset the fundamental financial instability and the precarious market position.

Keywords

fire safety equipment, business combination, going concern, Nasdaq delisting, revenue growth, capital raise, goodwill impairment, preferred stock